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A B S T R A C T
Fungi are a major threat in immunocompromised patients. Despite presenting similar degrees of
immunosuppression, not all individuals at-risk ultimately develop fungal diseases. The traditional view
of immune suppression as a key risk factor for susceptibility to fungal infections needs to be
accommodatedwithin new conceptual advances on host immunity and its relationship to fungal disease.
The critical role of the immune system emphasizes the contribution of host genetic polymorphisms to
fungal disease susceptibility. This review highlights the present knowledge on innate immunity genetics
that associates with susceptibility to fungal diseases.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In the last decades, modern and sophisticated medical care has
prolonged and improved the lives of many individuals suffering
from severely debilitating conditions. However, such advances
have also resulted in an increased risk for fungal diseases,
particularly among patients with prolonged neutropenia, treated
with corticosteroids, or submitted to bone-marrow or solid-organ
transplantation.1 Invasive fungal diseases are associated with
signiﬁcant morbidity and an estimated mortality exceeding 50% in
most studies.2 Mortality has been reported to be as high as 95% in
bone-marrow transplant recipientswith invasive aspergillosis (IA),
particularly in the context of disseminated disease.3 In addition to
Aspergillus species, several fungi have emerged as important
opportunistic pathogens, including species of Candida, Fusarium,
Scedosporium and the zygomycetes. Despite the availability of
drugs, the emergence of antifungal-resistant strains and the failure
of certain patients to respond to standard treatments have
emphasized the need for the development of novel therapeutic
agents.4–6 This involves the study of both the pathogens, in terms* Corresponding author. Tel./fax: +39 (0)75 5857498.
E-mail address: aacarvalho2008@gmail.com (A. Carvalho).
1 These authors contributed equally to this work.
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the host, whose own defense mechanisms determine the response
to the infectious challenge and the ensuing pathology. In this
regard, it is pertinent to acknowledge the variable degrees of
virulence often presented by different isolates of the same fungal
species (e.g., Paracoccidioides brasiliensis) that can contribute to the
development of more or less severe fungal disease, independently
of the genetic circumstances of the host.7 On the other hand,
regarding the host genetic background, signiﬁcantly varying
patterns of susceptibility are also known to be displayed by
different inbred strains of mice to the same fungal pathogen.8 Over
the last few years, signiﬁcant advances into the genetic basis of
immune disorders leading to severe and recurrent infections have
been made.9 It is now clear that host genetic factors play a major
role in determining differential susceptibility to infectious diseases
of humans. In this review, we will discuss major ﬁndings and
recent progress on the genetic variables of the innate immune
system contributing to susceptibility to fungal diseases.
2. Human genetics: exploring susceptibility to infectious
diseases
Differences in human susceptibility to infectious diseases have
been widely reported, the best known example being malaria.10
Although malaria illustrates a genetic variant of the host resultingses. Published by Elsevier Ltd. All rights reserved.
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genetic variants can lead to increased occurrence of infections. A
study comparing the causes of death among adopted children with
those of either their biological or adoptive parents concluded that
the risk of death from infection was increased 5.8-fold when
biological parents also prematurely died from the same cause.11
This study, which effectively separated genetic and environmental
confounders, conﬁrmed the substantial genetic effect involved in
susceptibility to infection.
Although humans are identical at most of the 3 billion base
pairs in their genome, inter-individual variation is present in
approximately 0.01% of the genome.12 The most common genetic
variation is the single nucleotide polymorphism (SNP), in which
two alternative bases occur at appreciable frequency (>1%) within
a population. Another type of genetic mutation is the variable
number of tandem repeats (VNTR), consisting of sequence repeats
ranging from a single to thousands of base pairs.13 Many genetic
variants are ‘silent’ with no effect on gene products. In general,
functionally signiﬁcant effects are most likely when polymorph-
isms are associated with amino acid substitutions in the gene
product, when a deletion/insertion results in a frameshift in the
coding region, or when the polymorphism directly affects gene
transcription, RNA splicing, mRNA stability or mRNA translation.
Only 1.5% of SNPs are thought to be located in the coding regions,
with the functions of nearly all SNPs located outside gene coding or
regulatory regions remaining unknown. These variations, how-
ever, are not randomly distributed within the genome, but rather
depend on the particular genomic region, as well as on selective
pressure.14 Hence, it is reasonable to speculate that genes involved
in important immune pathways represent a potential source of
variability regarding susceptibility to infectious diseases. In fact,
these attractive candidates have already prompted a number of
key human studies on genetic variation contributing to suscept-
ibility or outcome of fungal diseases, as discussed throughout this
review.
Human disease-association studies can identify multiple inter-
acting disease genes and respective pathways, providing a
comprehensive understanding of the etiology of disease. However,
as information on human genetic variability increases, it is critical
that study design and data analysis receives thorough attention toFigure 1. The structure ofMBL2 and the functional impact of SNPs inMBL2. The six loci of
representing the alleles for wild-type andmutant variants. Three are located at codons 52
codes for the formation of high-order oligomers is assigned the letter A. Three additional
50-ﬂanking region ofMBL2. Consequently, an individual expressing the sequence HYPwill
and P/Q should be possible, linkage disequilibrium leads to the formation of four mainensure that spurious associations are not reported and that genuine
diseasegenes are identiﬁed. Frequently citedconcerns inassociation
studies regard case deﬁnition. In this regard, it is imperative that
appropriate and uniform diagnostic criteria for the disease being
studied are used, especially if subgroup analysis involving the stage
or severity of the disease is performed. There are also several pitfalls
in control recruitment. Ideally, cases and controls should be
matched by ethnic origin, age, and gender. Moreover, it is also
important to note that the power for association detection depends
on several factors, including the frequency of risk allele/genotype,
the relative risk conferredbydisease-associated allele/genotype, the
correlation between the genotyped marker and risk allele, sample
size, disease prevalence and heterogeneity, and genetic hetero-
geneity of the sampled population.
3. Genetic variants of pattern recognition receptors and
susceptibility to fungal diseases
Host defense mechanisms inﬂuence both fungal disease
manifestation and severity. The immune system of vertebrates
consists of two inter-related components, the innate and adaptive
responses, jointly required for the resolution of most infections.15
The innate immune response is based on a restricted number of
evolutionarily conserved germline-encoded receptors, the pattern
recognition receptors (PRRs), which recognize highly conserved
microbial structures, enabling the host to rapidly recognize a broad
range of pathogens.16 Microbial recognition induces an inﬂam-
matory response through the production of cytokines and
chemokines, activating and recruiting other cells to the site of
infection, ultimately initiating the adaptive arm of the immune
response. During infection in vivo,microbial recognition is likely to
occur through multiple interactions at multiple sites involving
many receptors.
3.1. Soluble PRRs
The collectin subfamily of lectins includes members such as
mannose-binding lectin (MBL), pentraxin 3 (PTX3), and lung
surfactant proteins (SPs). MBL is known to strengthen the innate
immune response by interacting with pathogens and immunethemost commonmutations are shown above the gene, with the letters below them
, 54, and 57, encoding for variants D, B, and C, respectively. The wild-type allele that
polymorphisms at positions 550 (H/L),221 (Y/X), and +4 (P/Q) are located in the
produce high levels ofMBL.Whilst in theory, any combination sequence of H/L, Y/X,
promoter sequences: HYP, LYQ, LYP, and LXP.
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consistently associated with increased susceptibility to infections,
particularly when adaptive immunity is compromised (e.g., in
early childhood or following chemotherapy18,19). Two MBL genes
exist, named MBL1 and MBL2. Both are found on chromosome 10,
although work into MBL1 has found it to be a pseudogene;20
consequently, MBL in humans is only expressed by MBL2. Six
functional polymorphisms are known inMBL2, and eachmay affect
protein levels (Figure 1). Three are non-synonymous polymorph-
isms leading to amino acid changes, which dramatically reduce
functional MBL levels by impairing assembly of MBL monomers
into functional oligomers.21 Three additional polymorphisms are
located in the 50-ﬂanking region of MBL2, affecting transcriptional
activity, reducing levels of circulating MBL.22 Although MBL may
still be produced at a level which reﬂects its expression, the fact
that it is non-functional will manifest as a deﬁciency of MBL. Thus,
through the combination of structural and promoter polymorph-
isms, MBL concentrations can vary considerably in the apparently
healthy individual.
The variant D of MBL2 was shown to associate with chronic
cavitary pulmonary aspergillosis (CCPA), a subacute and slowly
destructive form of aspergillosis.23 Interestingly, unlike CCPA, no
signiﬁcant associationwas observed between the same variant and
allergic bronchopulmonary aspergillosis (ABPA), a hypersensitivity
disease affecting mainly patients with asthma or cystic ﬁbrosis.
However, ABPA patients showed a signiﬁcant association with the
G+1011A polymorphism in intron 1 of MBL2, resulting in
eosinophilia and elevated plasma MBL levels and MBL activity,
which is related with the pathogenesis of the disease.24 In
transplantation, the incidence of invasive fungal diseases after
allogeneic hematopoietic stem cell transplantation (HSCT) was
instead correlated with donor MBL-low genotypes.25 The same
authors reported an additional non-synonymous polymorphism in
MBL-associated serine protease 2 (MASP2), known to lead to
reduced MBL function, to be an independent predictive factor for
invasive fungal disease after HSCT, although this result deserves
further validation owing to the low number of recipients with the
MASP2 variant.25 Nevertheless, this study shows that independent
factors from both donors and recipients play an important role in
the outcome of bone-marrow transplantation.
Vulvovaginal candidiasis (VVC), together with its recurrent form
(rVVC), is one of themost prevalent vaginal infections. The variant B
ofMBL2 has been associatedwith either an increased risk26–29 or no
risk30 of rVVC or VVC, despite the fact that a reduction in vaginal
concentrations of MBL in women with rVVC has been consistently
observed in the presence of such variant.26,28,29 These observations
suggest that MBL deﬁciency could be an important risk factor for
rVVC. Additionally, low MBL plasma levels were also reported to
facilitate abdominal Candida infections in patients with secondary
peritonitis, independently of other risk factors.31 Despite this
evidence suggesting an important role ofMBL in Candida infections,
MBL2 polymorphisms were not associated with chronic dissemi-
nated candidiasis (CDC) in immunocompromised patients, particu-
larly those undergoing therapy for acute leukemia.32 This suggests
that additional innate immune gene polymorphisms may be
involved in susceptibility to Candida infection or, as recently
suggested, in Candida carriage.33 In this regard, diabetic or healthy
asymptomatic individualswhohavedetectable levels ofCandida spp
in theoral cavityhavea signiﬁcantly increased incidenceof thewild-
type allele at position 44 (C44G) in the DEFB1 gene encoding b-
defensin-1 (hBD-1).33 Since this polymorphism is located in the 50-
untranslated region of DEFB1, variations in the translation and/or
transcriptionofhBD-1mayexplain theexpressionvariabilityamong
individuals. However, its relevance to Candida carriage in HIV-
infectedpatients and the development of oropharyngeal candidiasis
is currently unknown.PTX3 is the type member of the pentraxin family, playing an
important role in microbe recognition and complement activa-
tion, acting non-redundantly against selected pathogens.34 For
instance, PTX3 may bind to Aspergillus conidia to facilitate
phagocytosis. Accordingly, whereas PTX3-null mice are highly
susceptible to IA,34 PTX3 administration was shown to have a
protective effect against IA in a murine model of allogeneic
HSCT.35 However, a study failed to associate polymorphisms in
the human PTX3 gene and susceptibility to particular phenotypes
of aspergillosis, although not all regions of PTX3 were sequenced
(Pasqualotto et al., unpublished data). Additionally, a high degree
of variability in PTX3 serum levels was observed, without any
obvious pattern of expression associatedwith disease phenotype.
Since the PTX3 gene exists in the human genome as an antisense
pair with the VEPH gene, studying the latter could be an
interesting approach.
Allele variants in SP-A2, one of the genes encoding for functional
SP-A, have also been shown to inﬂuence susceptibility to both
ABPA and CCPA.23,36 Although the precise effect of these
polymorphisms on SP-A function is yet unknown, increased levels
of total IgE antibodies and peripheral eosinophilia, as well as
decreased lung function, were suggested as the causes for ABPA
susceptibility.36 The occurrence of distinct genotype combinations
of SP-A2 and MBL2 in patients with pulmonary aspergillosis
suggests that variations in these genes may contribute to the
pathogenesis of the diverse clinical entities caused by the fungus.
It is of interest that the genetic bases for human disease
susceptibility may also be evaluated by the screening of inbred
murine strains. Recently, this approach was performed using an
immunocompromised mice model of IA.37 Through a haplotype-
based computational genetic analysis of the survival data, the
polymorphic gene encoding plasminogen (PLG), a regulatory
molecule that binds to Aspergillus, was identiﬁed as a suitable
candidate for Aspergillus susceptibility. Accordingly, a non-
synonymous polymorphism causing an amino acid change
(Asp472Asn) in human PLG was reported to affect the risk of
developing IA in HSCT recipients, particularly after day 40 post-
transplant.37 In addition, there was an apparent gene-dosage
effect: homozygous mutant individuals had a 5.6-fold increased
risk of developing IA while heterozygotes had a 3.0-fold increased
risk, relative to wild-type individuals. Besides shedding light into
the role of the ﬁbrinolytic system in the pathogenesis of IA, this
approach identiﬁed a novel, biologically plausible, positional
candidate gene, validating its use in the identiﬁcation of less
obvious disease-related genes.
To date, the vast majority of the genetic studies involving
soluble PRRs and susceptibility to fungal disease have focused on
the role of MBL. Indeed, a well-established link between
genetically determined deﬁciencies in MBL levels and suscept-
ibility to both mould and yeast infections in either immuno-
competent or immunosuppressed hosts has been proposed
(reviewed in Table 1). Genetic variants affecting other soluble
molecules of crucial relevance in host antifungal defense,
including proteins from the lung surfactant and b-defensins,
have also been shown to inﬂuence susceptibility to fungal
diseases.23,33,36 On the other hand, polymorphisms in PTX3 were
demonstrated to be unlikely determinant factors of susceptibility
to aspergillosis (Pasqualotto et al., unpublished data). Despite
these advances, further studies identifying additional genes
involved in fungal susceptibility are required. The recent
approach developed by Zaas et al. using an immunocompromised
mice model of IA represents a promising methodology to be used
in the discovery of candidate genes involved in fungal disease,37
information which will eventually allow the uncovering of
additional human genetic variations putatively implicated in
fungal disease.
Table 1
Human genetic association studies evaluating polymorphisms in soluble pattern recognition receptors (PRRs) and susceptibility to fungal diseases
Reference Association
study
Gene SNPs/haplotypes Relevant ﬁndings
Vaid et al.23 CCPA MBL2 Variant D
(codon 52)
The variant allele (p  0.02) and genotype (p  0.05) were associated with CCPA (n=15),
but not ABPA
Donders et al.27 rVVC MBL2 Variant B
(codon 54)
Women suffering from rVVC (n=109) were more likely to carry the variant B of MBL2
than controls (20 vs. 6.6%, p=0.01)
Liu et al.29 VVC MBL2 Variant B
(codon 54)
Cervicovaginal MBL concentrations and gene variant frequency were both signiﬁcantly
higher in women with VVC (n=51) than controls (p<0.01)
Kaur et al.24 ABPA MBL2 G+1011 A signiﬁcant association of high MBL levels with ABPA (n=11) in comparison to the
controls (p<0.01) was observed
Granell et al.25 IA MBL2 O/O or LXA/Oa Donor MBL-low genotype (38% vs. 12%, p=0.01) was associated with a higher
probability of IA in HSCT (n=106 donor–patient sibling pairs)
van Till et al.31 AYI MBL2 A/O or O/O A higher proportion of variant patients had an AYI during early peritonitis than
wild-type patients (n=88) (39% vs.16%, p=0.012)
Saxena et al.36 ABPA SP-A2 G+1649C and
A+1660G
SP-A2 polymorphisms contribute to genetic predisposition and severity of clinical
markers of ABPA (n=10)
Vaid et al.23 CCPA SP-A2 G+1649C The C/C genotype was signiﬁcantly associated with CCPA (n=12) (p  0.05)
Zaas et al.37 IA PLG Asp472Asn Risk of IA at day >40 after HSCT was 5.6-fold higher in Asn/Asn vs. Asp/Asp
individuals (n=83 IA cases)
Granell et al.25 IA MASP2 Asp105Gly Recipient MASP2 variant (67% vs. 14%, p=0.01) was associated with a higher
probability of IA in HSCT (n=106 donor-patient sibling pairs)
Jurevic et al.33 Candida carriage DEFB1 C44G A strong association with Candida carriage was observed in both diabetic
(n=43) and non-diabetic individuals
ABPA, allergic bronchopulmonary aspergillosis; AYI, abdominal yeast infection; CCPA, chronic cavitary pulmonary aspergillosis; DEFB1, b-defensin-1; HSCT, hematopoietic
stem cell transplantation; IA, invasive aspergillosis;MASP2,MBL-associated serine protease 2;MBL,mannose-binding lectin; PLG, plasminogen; rVVC, recurrent vulvovaginal
candidiasis; SNP, single nucleotide polymorphism; SP-A2, surfactant protein A2; VVC, vulvovaginal candidiasis.
a O/O and LXA/O are MBL-low haplotypes. LX represents an MBL promoter haplotype. Variants D, B and C are collectively named O, while A indicates the wild-type.
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The Drosophila protein Toll, originally identiﬁed as a trans-
membrane receptor required for the establishment of dorso-
ventral polarity in developing ﬂy embryos,38 was shown to be
required to mount effective antifungal responses.39 The observa-
tion that Toll-deﬁcient Drosophila were highly susceptible to
fungal infection led to the assumption that mammalian TLRs also
participated in antifungal immunity. In fungal infections, the
different impact of TLRs on the innate and adaptive immunity is
consistent with the ability of each individual TLR to activate
specialized antifungal effector functions on innate immune cells,
such as the respiratory burst, degranulation, and production of
chemokines and cytokines.40–42 TLR2, TLR4, and TLR9 signaling hasFigure 2. The Asp299Gly polymorphism of the TLR4 gene may represent a ‘double-edge
domain may be hampering its function by impairing microbial recognition, eventuall
colonization. However, failure to recognize the fungus may be compensated by the lack o
host, thus resulting in a protective effect from fungal infection.been shown to contribute to host responses against fungi both in
mice (reviewed in ref. 43) and humans.44
Two important co-segregated polymorphisms – Asp299Gly and
Thr399Ile – resulting in lipopolysaccharide (LPS) hyporesponsive-
ness, are present in the TLR4 gene.45 These polymorphisms were
described to be present at a substantially higher proportion among
individuals hyporesponsive to inhaled LPS. Epithelial cells derived
from these individuals were found to be unable to mediate LPS
signaling in vitro.45 This report was followed by several studies
conﬁrming an association between these polymorphisms and the
incidence of septic shock due to Gram-negative bacteria.46
Regarding fungal disease, the Asp299Gly polymorphism was
recently shown to be associated with susceptibility to CCPA44
and IA in allogeneic HSCT recipients of unrelated donors.47 The factd sword’ in allogeneic stem cell transplantation. The abnormal TLR4 extracellular
y leading to fungal escape from immune surveillance and predisposing to fungal
f an exuberant inﬂammatory response to it, whichmay ultimately be harmful to the
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polymorphism in HSCT recipients to susceptibility to IA48 indicates
that the contribution of this SNP may depend on the type of
transplant. Additionally, in allogeneic HSCT recipients, we have
recently observed an association between the presence of
Asp299Gly and fungal colonization but not fungal pneumonia.49
Therefore, fungal colonization may not predict susceptibility to
infection in the presence of Asp299Gly. The positive correlation of
this SNP with fungal colonization could be explained by the fact
that the presence of an abnormal TLR4 extracellular domain may
hamper its function by disrupting microbial recognition, even-
tually leading to fungal escape from immunosurveillance
(Figure 2). However, TLR4 polymorphisms have also been shown
to have a protective effect in diseases associated with hyperin-
ﬂammatory states.50 Therefore, the failure to recognize the fungus
may be compensated by the lack of an exuberant inﬂammatory
response to it which may ultimately be harmful to the host. In this
regard, we have recently found that a hyperinﬂammatory state,
more than the fungus itself, may contribute to susceptibility to
aspergillosis and other fungal infections.4 Thus, by limiting the
inﬂammatory response to the fungus, the Asp299Gly polymorph-
ism could contribute to resistance to infection, despite evidence of
fungal growth. It is interesting in this regard that the Asp299Gly
polymorphism was recently shown to have a unique distribution
with high prevalence in Africa and low prevalence in Europe, with
the authors arguing that the beneﬁt from reduced inﬂammation
during malaria in Africa might have been counter-selected due to
lack of inﬂammation in response to bacterial infections.51
The same TLR4 polymorphisms were shown to contribute to a
higher risk of Candida bloodstream infection, supposedly through
an increased interleukin (IL)-10 production.52 Patients with
chronic mucocutaneous candidiasis (CMC) were also reported to
have increased IL-10 over interferon-g (IFN-g) production,
possibly occurring in association with Asp299Gly.53 However,
the extent to which these polymorphisms contribute to the
hyperactivation immune status of CMC patients with autoimmune
regulator (AIRE) gene mutations54 is not known. IL-10 has been
reported to inhibit the action of humanmonocytes against Candida
albicans, while in mice, the absence of IL-10 was associated with
increased antifungal resistance. However, in experimental candi-
diasis, IL-10 exhibited both beneﬁcial and detrimental effects
depending on the degree of inﬂammation (reviewed in ref. 55).
Therefore, despite the overall suppressive effect, IL-10 might be
required to limit host damage under high levels of inﬂammation.
This may explain why the Asp299Gly polymorphism does not
appear to play a role in susceptibility and severity of human
urogenital C. albicans infection.56
TLR2 is also known to recognize motifs from fungal pathogens
and initiate immune responses. A TLR2-dependent IL-10 produc-
tion was demonstrated in response to Candida and Aspergillus in
experimental models of infection.57,58 However, no association
between the non-synonymous polymorphism in human TLR2
(Arg753Gln) and susceptibility to IA, CCPA, or ABPA was
found.44,48,49 In candidiasis, the Arg753Gln polymorphism was
shown to impact cytokine release, namely reduced IFN-g and IL-8
and increased tumor necrosis factor-a (TNF-a) during Candida
sepsis in intensive care unit (ICU) patients.59 However, the extent
to which the deregulated cytokine production contributes to
susceptibility to candidiasis is not clear.
TLR9 is a receptor that detects unmethylated CpG motifs
prevalent in bacterial and viral DNA.60 Recently, Aspergillus
fumigatus DNA was also shown to activate immune responses
through TLR9-dependent recognition.61 In humans, two variants
were identiﬁed within the TLR9 promoter, as well as a number of
rare non-synonymous SNPs within the coding sequence.62 An
association of a promoter polymorphism, T1237C, with asthmawas reported, whereas no signiﬁcant results were found regarding
the other variants.62 T1237C was also demonstrated to be
involved in susceptibility to atopic eczema, and an altered TLR9
expression was considered to underlie this putative association.63
Interestingly, we recently reported an association between
T1237C and the development of ABPA, but not severe asthma
with fungal sensitization (SAFS)44 or IA in allogeneic HSCT.49 This
was the ﬁrst study to show that subtle genetic differences may
occur between the two similar allergic groups of ABPA and SAFS
patients.
Less well-characterized genetic variants in other TLRs, includ-
ing TLR1 and TLR6, have also been reported to inﬂuence
susceptibility to acute IA after allogeneic HSCT.48 Transplant
recipients harboring either one polymorphism in TLR1 (Arg80Thr)
or a polymorphism combination in TLR1 and TLR6 (Asn248Ser and
Ser249Pro) have an increased risk of invasive fungal disease.48
Again, the fact that polymorphisms in HSCT recipients have been
associated with aspergillosis suggests that other components in
addition to hematopoietic cells play an important role in the
recognition of Aspergillus ligands.
C-type lectin receptors (including dectin-1) are major mam-
malian PRRs for several fungal components and are the prototype
of innate non-TLR signaling pathways for innate antifungal
sensing.64 Dectin-1 is a myeloid-expressed transmembrane
receptor that speciﬁcally recognizes the cell wall carbohydrates
b-1,3-glucans of many fungi, mediating myeloid cell activation,
cytokine production, and a variety of antifungal responses.64
Recently, a polymorphism in human dectin-1 that generates an
early stop codon was identiﬁed and associated with an increased
risk of mucocutaneous candidiasis (reviewed in ref. 65). This SNP
was shown to result in impaired transport of dectin-1 to the cell
surface as well as failure in mediating b-glucan binding.65 In fact,
individuals homozygous for this polymorphism lack expression of
this receptor on the surface of their myeloid cells, and therefore
these cells do not respond tob-glucan. Nevertheless, and although
patients harboring this mutation presented defective cytokine
production, the normal phagocytosis and killing capacity displayed
by neutrophils and macrophages could explain why this dectin-1
deﬁciency was not associated with invasive fungal diseases.65
Genetic studies elucidating the role of membrane-bound PRRs
havemainly focused on TLR4, and in particular, on a coding variant
affecting the extracellular domain of the receptor (reviewed in
Table 2). A recent study by Bochud et al. demonstrated that the
TLR4 variant Asp299Gly on the donor side was an independent
predisposing factor to IA following HSCT.47 In this regard, work
from our group has also recently demonstrated that the same
variant, while predisposing to fungal colonization, was none-
theless associated with resistance to fungal pneumonia of
colonized patients.49 The Asp299Gly polymorphism had been
previously described to contribute to both increased susceptibility
to CCPA44 and Candida bloodstream infection.52 Despite the
increasing amount of data regarding genetic variability of TLRs,
considerationmust also be given to the role played by non-TLRs. In
this regard, recent work evaluating polymorphisms in dectin-1,64
together with the understanding of their functional impact,
assures new research possibilities regarding the inﬂuence of the
host genetic background in fungal susceptibility.
3.3. Cytokines
Cytokines mediate the inﬂammatory and adaptive responses to
fungi. The inﬂammatory response may serve to limit infection, but
an overzealous or heightened inﬂammatory response may con-
tribute signiﬁcantly to the histological patterns and pathogenicity,
as documented by the occurrence of severe fungal infections in
patients with immune reconstitution disease.4–6 Th1 cytokines
Table 2
Human genetic association studies evaluating polymorphisms in Toll-like receptors (TLRs) and susceptibility to fungal diseases
Reference Association
study
Gene SNPs/haplotypes Relevant ﬁndings
Carvalho et al.44 CCPA TLR4 Asp299Glya A signiﬁcant association was observed between Asp299Gly and CCPA (n=40) (p=0.003)
Bochud et al.47 IA TLR4 Asp299Glya An association between donor Asp299Gly and risk of IA among recipients of HSCT from
unrelated donors was observed, especially if combined with CMV positivity (n=103 IA cases)
Carvalho et al.49 IA TLR4 Asp299Glya Donor Asp299Gly was associated with fungal colonization following HSCT (p=0.003),
while susceptibility to fungal pneumonia was instead decreased in the presence of the
same SNP (p=0.03)
Van der Graaf et al.52 BSI TLR4 Asp299Glya The prevalence of Asp299Gly was higher in patients with Candida BSI (n=43) than
in controls (26% vs. 10%)
Carvalho et al.44 ABPA TLR9 T1237C Susceptibility to ABPA (n=22) was associated with T1237C (p=0.043)
Kesh et al.48 IA TLR1
TLR6
Arg80Thr
Asn248Ser,
Ser249Pro
Analysis of recipient SNPs showed that the presence of TLR1 Arg80Thr or the presence
of both TLR1 Asn248Ser and TLR6 Ser249Pro was associated with IA (n=22 IA cases) (p<0.001)
ABPA, allergic bronchopulmonary aspergillosis; BSI, bloodstream infection; CCPA, chronic cavitary pulmonary aspergillosis; CMV, cytomegalovirus; HSCT, hematopoietic
stem cell transplantation; IA, invasive aspergillosis; SNP, single nucleotide polymorphism; TLR, Toll-like receptor.
a The Asp299Gly polymorphism was co-segregated with Thr399Ile.
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However, other cytokines and T cell-dependent pathways are also
involved in antifungal immune responses.42
In terms of pro-inﬂammatory cytokine production, a poly-
morphism in the TNF promoter (G-308A) is responsible for variable
cytokine levels. The high-producing A/A genotypewas shown to be
less common in patients with aspergillosis.66 Accordingly, in vitro
studies have demonstrated that TNF-a enhances speciﬁc phago-
cytic activity against conidia by pulmonary alveolar macrophages
and augments the neutrophil damage of Aspergillus hyphae.67
However, a lack of association between TNF polymorphisms and IA
has also been described. In this study, a polymorphic site in the
promoter of TNF receptor 2 (TNFR2) was instead reported to
predispose to IA.68
The pro-inﬂammatory cytokine IL-1 is encoded by two separate
genes, IL1A (IL-1a) and IL1B (IL-1b), located in a cluster that also
contains the IL-1 receptor antagonist (IL1RN).69 No associationwas
found between the presence of IA and individual locus analysis of
the IL1A (C889T), IL1B (T511C), and IL1RN (86-bp VNTR)
polymorphisms.70 Nevertheless, haplotype analysis revealed that
VNTR2/889C/511T was strongly associated with susceptibility
to develop IA, whereas a link between the VNTR2/889C/511C
haplotype and resistance to IA was reported,70 supporting the
hypothesis that the IL1 gene cluster may determine susceptibility
to IA, although the precise mechanisms are yet unclear. IL-6 also
contributes to the inﬂammatory response to fungi.4 However, IL6
polymorphisms failed to associate with IA.71 Nevertheless, the IL6
polymorphisms, together with those from the IL1 gene cluster,
appear to be involved in themodulation of C-reactive protein (CRP)
levels, since a positive correlation with CRP values was found,
although the authorswere unable to link the circulating CRP values
with the pathogenesis of IA infection.
IFN-g is able to potentiate the antifungal activity of human
phagocytic cells,72 with a higher IFN-g/IL-10 ratio contributing to a
favorable response to antifungal therapy in patients with clinical
evidence of IA.73 Although high levels of IFN-g resulting from
homozygous carriage of the T+874A polymorphism in the IFNG
gene were associated with aspergillosis,66 patients with inborn
errors of the IL-12/IL-23/IFN-g-mediated immunity were reported
to be susceptible to disseminated paracoccidioidomycosis74 and
histoplasmosis.75
IL-4 has been suggested as the ﬁrst determinant of T cell
differentiation into Th2 cytokine-producing cells during fungal
diseases.72 Frequent polymorphisms in the IL-4 receptor (IL4R) of
ABPA patients, in particular Ile75Val, were associated with IL-4-
induced up-regulation of CD23 expression.76 The increased
sensitivity of ABPA patients to IL-4 was proposed as a contributing
factor to increased B-cell activity eventually leading to Aspergillus-speciﬁc Th2 responses.77 In candidiasis, a promoter polymorphism
of IL4 (C589T) was identiﬁed, and homozygous carriage of the T
allele, linked with increased IL-4 production, was associated with
rVVC.78 Since IL-4 blocks macrophage-mediated anti-Candida
responses, at least in part by the inhibition of NO production,
elevated IL-4 levels were suggested to compromise immune
responses to Candida in rVVC. Accordingly, a common haplotype in
the IL4 promoter (1098T/589C/33C) was also associated with
CDC.79 Nonetheless, a protective effect from another haplotype
(1098T/589T/33T) was also reported, suggesting that IL4
variants may differently affect susceptibility to candidiasis.
As already mentioned, IL-10 may have positive and negative
effects on immune responses to fungi.55 Elevated IL-10 levels were
associated with IA and linked to unfavorable outcome in non-
neutropenic immunocompromised patients.80 A common poly-
morphism in the IL10 promoter (G1082A) affecting transcrip-
tional activity has been associated with altered IL-10 serum levels.
The high-producing G/G genotype has been linked with both
increased Aspergillus colonization andABPA in patientswith cystic
ﬁbrosis.81 In contrast, the common IL10 promoter haplotype ACC
(1082A/819C/592C) has been shown to protect from IA after
HSCT, although no correlation with IL-10 serum levels was
estimated.82 Additionally, despite being protective against IA in
allogeneic HSCT,83 the low-producing A/A genotype was also
linked with CCPA,66 suggesting that failure to control the
inﬂammatory response could underlie the development of CCPA.
As a matter of fact, CCPA patients were shown to be lower
producers of transforming growth factor-b (TGF-b) as compared
with thosewith allergic disease,mostly due to lower frequencies of
the high-producing T/T genotype (T+869C) of the TGFB1 gene.66
Recently, data has also pointed to the relevance of genetic
variants in chemokine genes in host susceptibility to fungal
diseases. A large-scale screening of polymorphisms led to the
ﬁnding of three markers in CXC chemokine ligand 10 (CXCL10;
C+11101T, C+1642G, and A1101G) resulting in increased
susceptibility to IA after HSCT.84 Furthermore, immature wild-
type dendritic cells exposed to A. fumigatus showed a markedly
increase in CXCL10 expression, in contrast to those harboring the
risk haplotype. In this regard, it is also interesting to note that
patients who survived IA had signiﬁcantly higher CXCL10 levels in
comparison to healthy controls.
In general, polymorphisms affecting cytokine function and
expression have been mostly studied regarding aspergillosis. In
fact, genetic variants leading to defects in levels of several pro-
inﬂammatory and anti-inﬂammatory cytokines have been linked
with susceptibility to aspergillosis in its various forms (reviewed in
Table 3). Particular emphasis has been given to the understanding
of genetic variation in the IL10 gene. In this case, consistent
Table 3
Human genetic association studies evaluating polymorphisms in cytokines and susceptibility to fungal diseases
Reference Association
study
Gene SNPs/haplotypes Relevant ﬁndings
Sainz et al.70 IA IL1RN,
IL1A, IL1B
VNTR2/889C/511T
VNTR2/889C/511C
The VNTR2/889C/511T haplotype was associated with IA, whereas
VNTR2/889C/511C was shown to be protective against the development
of IA (n=59 IA cases)
Seo et al.82 IA IL10 1082A/819C/592C The IL10 ACC haplotype had an apparent protective role in the development
of IA after allogeneic transplantation (n=105 HSCT patients; 9.9% IA cases)
Sainz et al.83 IA IL10 G1082A The IL10 A/A low-producing genotype was associated with resistance to
develop IA (n=59 IA cases) (p=0.001)
Brouard et al.81 ABPA IL10 G1082A A signiﬁcant relationship was found between the IL10 G/G high-producing
genotype and both colonization with Aspergillus fumigatus and ABPA
(n=378 CF patients)
Sambatakou et al.66 CCPA IL10 G1082A CCPA (n=24) was associated with lower frequency of the G allele (p=0.0006)
and G/G genotype (p<0.001)
Sainz et al.68 IA TNFR2 VNTR at 322 Susceptibility to IA was associated with VNTR at position 322 in the
promoter region of TNFR2 (n=54 IA cases) (p=0.029)
Knutsen et al.76 ABPA IL4R Ile75Val IL4R SNPs were observed in 95% of ABPA patients, with the Ile75Val
polymorphism observed in 80% of ABPA patients (n=40)
Babula et al.78 rVVC IL4 C589T The T/T genotype was detected in 59.5% of patients with rVVC (n=42),
with a correlation between homozygosity and increased vaginal
IL-4 levels (p<0001)
Choi et al.79 CDC IL4 1098T/589C/33C
1098T/589T/33T
The TCC haplotype was overrepresented in patients with CDC (n=40)
(p=0.01), whereas the TTT haplotype appeared to be protective
against CDC (p=0.018)
Sambatakou et al.66 ABPA/CCPA IL15 A+13689T Both ABPA (n=9) and CCPA (n=24) were associated with a higher
frequency of the high-producing A allele (p=0.0028) and A/A
genotype (p<0.001)
Sambatakou et al.66 ABPA/CCPA TNF A308G Both ABPA (n=9) and CCPA (n=24) were associated with a lower
frequency of the high-producing A/A genotype (p<0.01)
Sambatakou et al.66 ABPA/CCPA IFNG T+874A A higher frequency of the high-producing T/T genotype, although not with
the T allele, and CCPA (n=24) and ABPA (n=9) was found
Sambatakou et al.66 CCPA TGFB1 T+869C CCPA (n=24) was associated with a lower frequency of the high-producing
T allele (p<0.0029) and T/T genotype (p<0.001)
Mezger et al.84 IA CXCL10 C+11101T, C+1642G
and A1101G
CXCL10 SNPs were associated with IA in allogeneic HSCT recipients
(n=81 IA cases) (p=0.007, 0.003, 0.001, respectively)
ABPA, allergic bronchopulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; CDC, chronic disseminated candidiasis; CF, cystic ﬁbrosis; HSCT,
hematopoietic stem cell transplantation; IA, invasive aspergillosis; IFN, interferon; IL, interleukin; rVVC, recurrent vulvovaginal candidiasis; SNP, single nucleotide
polymorphism; TNF, tumor necrosis factor; TGF, transforming growth factor; VNTR, variable number of tandem repeats.
A. Carvalho et al. / International Journal of Infectious Diseases 14 (2010) e460–e468e466associations between low IL-10-producing genotypes and
increased susceptibility to aspergillosis have been reported.66,81–
83 In contrast, polymorphisms in IL4 appear instead to have a
speciﬁc impact on susceptibility to Candida diseases.78,79 In
addition to cytokines, chemokines are also thought to play an
important role in the host antifungal defense. The fact that
polymorphisms affecting CXCL10 were recently reported to
predispose to IA following HSCT84 further reinforces the need to
look beyond cytokines and to explore new avenues of research,
leading to a more integrated view of immune defects and their
contribution to susceptibility to fungal diseases.
4. Conclusions
Although the dissection of complex traits of host immune
genetics into susceptibility to fungal diseases is complex, the
contribution of host genetics may hold the key to elucidation of
new risk factors for these severe, often fatal diseases. Although the
overall functional signiﬁcance of the ﬁndings discussed in this
review cannot be underestimated, there is an obvious need to
independently replicate some of the studies with smaller sample
power. In addition, considering the key role played by many of
these polymorphisms at the host–fungus interface, further large-
scale clinical and translational studies are needed to conﬁrm the
data obtained from human cohorts.
Understanding host–pathogen interactions at the level of host
genetic susceptibility, together with the molecular and cellular
bases affected, will allow the identiﬁcation of potential therapeutic
targets and the design of prophylactic strategies exerting control
over the outcome of innate immune pathways. The genomicscreening of at-risk patients may ultimately be used to individua-
lize treatment through the formulation of new targeted and
patient-tailored antifungal therapeutics, which are likely to
improve the management and outcome of fungal diseases.
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